RT @doctorRBC: Bimekizumab (dual IL-17F and IL-17A inhibitor) phase 3 study for treatment of active ankylosing spondylit
Tweet Content
Bimekizumab (dual IL-17F and IL-17A inhibitor) phase 3 study for treatment of active ankylosing spondylitis demonstrated ASAS40 improvement at wk 14 (44% vs. 25%).
#EULAR2022 @RheumNow #ABSTOP0019 https://t.co/eohvNFG3GS
Show on Archive Page
On
Display in Search Results
On
PDQ
Off